180 related articles for article (PubMed ID: 21253392)
1. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
Klaus J; Reinshagen M; Herdt K; Schröter C; Adler G; von Boyen GB; von Tirpitz C
World J Gastroenterol; 2011 Jan; 17(3):334-42. PubMed ID: 21253392
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.
Klaus J; Reinshagen M; Herdt K; Adler G; von Boyen GB; von Tirpitz C
J Gastrointestin Liver Dis; 2011 Jun; 20(2):141-8. PubMed ID: 21725510
[TBL] [Abstract][Full Text] [Related]
3. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.
von Tirpitz C; Klaus J; Steinkamp M; Hofbauer LC; Kratzer W; Mason R; Boehm BO; Adler G; Reinshagen M
Aliment Pharmacol Ther; 2003 Mar; 17(6):807-16. PubMed ID: 12641503
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
5. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease.
von Tirpitz C; Klaus J; Brückel J; Rieber A; Scholer A; Adler G; Böhm BO; Reinshagen M
Eur J Gastroenterol Hepatol; 2000 Jan; 12(1):19-24. PubMed ID: 10656205
[TBL] [Abstract][Full Text] [Related]
6. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of monthly ibandronate in men with low bone density.
Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
Senn C; Günther B; Popp AW; Perrelet R; Hans D; Lippuner K
Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
[TBL] [Abstract][Full Text] [Related]
9. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
Shin K; Park SH; Park W; Baek HJ; Lee YJ; Kang SW; Choe JY; Yoo WH; Park YB; Song JS; Lee SG; Yoo B; Yoo DH; Song YW
Clin Ther; 2017 Feb; 39(2):268-278.e2. PubMed ID: 28161119
[TBL] [Abstract][Full Text] [Related]
10. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Miller PD; Recker RR; Reginster JY; Riis BJ; Czerwinski E; Masanauskaite D; Kenwright A; Lorenc R; Stakkestad JA; Lakatos P
Osteoporos Int; 2012 Jun; 23(6):1747-56. PubMed ID: 21953471
[TBL] [Abstract][Full Text] [Related]
12. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
15. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial).
Ringe JD; Farahmand P; Schacht E; Rozehnal A
Rheumatol Int; 2007 Mar; 27(5):425-34. PubMed ID: 17216477
[TBL] [Abstract][Full Text] [Related]
16. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
[TBL] [Abstract][Full Text] [Related]
17. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
[TBL] [Abstract][Full Text] [Related]
18. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
[TBL] [Abstract][Full Text] [Related]
19. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis.
Rubin CD; Pak CY; Adams-Huet B; Genant HK; Li J; Rao DS
Arch Intern Med; 2001 Oct; 161(19):2325-33. PubMed ID: 11606148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]